Latest period
$1.40B
YoY change
+5.0%
5Y CAGR
+11.7%
Peak year (2025)
$1.31B
Cumulative CapEx
$29.77B
CapEx history chart for Bristol-Myers Squibb (BMY) from 1989 to 2025
Latest: $1.31B
CapEx growth chart for Bristol-Myers Squibb (BMY) from 1989 to 2025
Latest: +5.0%
CapEx history table for Bristol-Myers Squibb (BMY) from 1989 to 2025
| 2025 | $1.31B | +5.0% | +$63.00M | ||
| 2024 | $1.25B | +3.2% | +$39.00M | ||
| 2023 | $1.21B | +8.1% | +$91.00M | ||
| 2022 | $1.12B | +14.9% | +$145.00M | ||
| 2021 | $973.00M | +29.2% | +$220.00M | ||
| 2020 | $753.00M | -9.9% | −$83.00M | ||
| 2019 | $836.00M | -12.1% | −$115.00M | ||
| 2018 | $951.00M | -9.9% | −$104.00M | ||
| 2017 | $1.05B | -13.2% | −$160.00M | ||
| 2016 | $1.22B | +48.2% | +$395.00M | ||
| 2015 | $820.00M | +55.9% | +$294.00M | ||
| 2014 | $526.00M | -2.0% | −$11.00M | ||
| 2013 | $537.00M | -2.0% | −$11.00M | ||
| 2012 | $548.00M | +49.3% | +$181.00M | ||
| 2011 | $367.00M | -13.4% | −$57.00M | ||
| 2010 | $424.00M | -41.9% | −$306.00M | ||
| 2009 | $730.00M | -22.4% | −$211.00M | ||
| 2008 | $941.00M | +11.6% | +$98.00M | ||
| 2007 | $843.00M | +6.3% | +$50.00M | ||
| 2006 | $793.00M | +3.3% | +$25.00M | ||
| 2005 | $768.00M | -5.1% | −$41.00M | ||
| 2004 | $809.00M | -18.3% | −$181.00M | ||
| 2003 | $990.00M | -16.2% | −$192.00M | ||
| 2002 | $1.18B | +15.5% | +$159.00M | ||
| 2001 | $1.02B | +73.7% | +$434.00M | ||
| 2000 | $589.00M | -16.9% | −$120.00M | ||
| 1999 | $709.00M | -10.0% | −$79.00M | ||
| 1998 | $788.00M | +2.7% | +$21.00M | ||
| 1997 | $767.00M | +27.6% | +$166.00M | ||
| 1996 | $601.00M | +17.2% | +$88.00M | ||
| 1995 | $513.00M | -10.5% | −$60.00M | ||
| 1994 | $573.00M | +0.5% | +$3.00M | ||
| 1993 | $570.00M | -11.9% | −$77.00M | ||
| 1992 | $647.00M | +3.0% | +$19.00M | ||
| 1991 | $628.00M | +22.4% | +$115.00M | ||
| 1990 | $513.00M | -7.6% | −$42.00M | ||
| 1989 | $555.00M | — | — |
- 2025$1.31B+5.0%
- 2024$1.25B+3.2%
- 2023$1.21B+8.1%
- 2022$1.12B+14.9%
- 2021$973.00M+29.2%
- 2020$753.00M-9.9%
- 2019$836.00M-12.1%
- 2018$951.00M-9.9%
- 2017$1.05B-13.2%
- 2016$1.22B+48.2%
- 2015$820.00M+55.9%
- 2014$526.00M-2.0%
- 2013$537.00M-2.0%
- 2012$548.00M+49.3%
- 2011$367.00M-13.4%
- 2010$424.00M-41.9%
- 2009$730.00M-22.4%
- 2008$941.00M+11.6%
- 2007$843.00M+6.3%
- 2006$793.00M+3.3%
- 2005$768.00M-5.1%
- 2004$809.00M-18.3%
- 2003$990.00M-16.2%
- 2002$1.18B+15.5%
- 2001$1.02B+73.7%
- 2000$589.00M-16.9%
- 1999$709.00M-10.0%
- 1998$788.00M+2.7%
- 1997$767.00M+27.6%
- 1996$601.00M+17.2%
- 1995$513.00M-10.5%
- 1994$573.00M+0.5%
- 1993$570.00M-11.9%
- 1992$647.00M+3.0%
- 1991$628.00M+22.4%
- 1990$513.00M-7.6%
- 1989$555.00M—
CapEx values are taken from Bristol-Myers Squibb's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Bristol-Myers Squibb (BMY)
According to Bristol-Myers Squibb's latest reported financial statements, the company's current CapEx (TTM) is $1.40B. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Bristol-Myers Squibb (BMY) CapEx totalled $1.31B – grew 5.0% year-over-year.
Bristol-Myers Squibb CapEx compound annual growth for the 2020–2025 (5 years) window is +11.7%, sustaining 5 straight years of year-over-year growth.
Across the available history, CapEx reached its high of $1.31B in 2025 and its low of $367.00M in 2011.
Bristol-Myers Squibb Capital Expenditures by Year
Bristol-Myers Squibb Capital Expenditures 2025: $1.31B
Bristol-Myers Squibb CapEx in 2025 was $1.31B, grew 5.0% from 2024. This figure represents the highest annual value in the available history.
Bristol-Myers Squibb Capital Expenditures 2024: $1.25B
2024's CapEx for Bristol-Myers Squibb came in at $1.25B, edged up 3.2% from 2023.
Bristol-Myers Squibb Capital Expenditures 2023: $1.21B
Bristol-Myers Squibb posted CapEx of $1.21B in 2023, grew 8.1% from 2022.
Bristol-Myers Squibb Capital Expenditures 2022: $1.12B
In 2022, Bristol-Myers Squibb reported CapEx of $1.12B, grew 14.9% from 2021.
Bristol-Myers Squibb Capital Expenditures 2021: $973.00M
Bristol-Myers Squibb CapEx in 2021 was $973.00M.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers by CapEx
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $5.91B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $5.91B
- $4.83B
- $4.11B
- $3.62B
- $1.86B
- $1.21B
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation